Crispr Therapeutics price target lowered to $53 from $59 at Stifel
Stifel lowered the firm’s price target on Crispr Therapeutics (CRSP) to $53 from $59 and keeps a Hold rating on the shares following the ...
Leaning into the Trump trade side of election outcomes, says Stifel's Brian Gardner
Cornell Belcher, Brilliant Corners Research's founder and president, and Brian Gardner, Stifel's chief Washington policy ...
Yahoo Finance1d
OnKure to Present at the Stifel 2024 Healthcare Conference
will present a corporate overview at the Stifel Healthcare Conference, on November 18, 2024 at 1:50 p.m. ET in New York, NY ...
InvestmentNews5d
B. Riley keeps indy reps after selling employees to Stifel for far less than expected
Eric Lyon, a former senior managing director, B. Riley Wealth Management, jumped to Kestra Investment Services at the start ...
Stifel Nicolaus Keeps Their Sell Rating on Alpha and Omega (AOSL)
Stifel Nicolaus analyst Tore Svanberg maintained a Sell rating on Alpha and Omega (AOSL – Research Report) today and set a price target ...
B. Riley to sell part of wealth management business to Stifel
Investment bank B. Riley Financial said on Friday it had agreed to sell a portion its traditional wealth management business ...
B. Riley Sells Part of Wealth Unit to Stifel Amid Broker Exits
B. Riley Financial Inc. agreed to sell a portion of its wealth-management business to Stifel Financial Corp. for as much as ...
Monitordaily13d
Stifel Receives Final Approval for Private Equity Fund
Stifel Financial received final federal approval for its Stifel North Atlantic AM-Forward Fund, which is designed to provide ...
InvestmentNews12d
Advisor recruiting slips at Stifel, surges at Raymond James
Take Raymond James Financial Inc. and Stifel Financial Corp., both of which reported quarterly earnings this week. Stifel ...
Personalis to Present at the Stifel 2024 Healthcare Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the Stifel 2024 Healthcare Conference on Tuesday, ...
Business Insider1d
Portillo’s downgraded to Hold from Buy at Stifel
Stifel analyst Chris O’Cull downgraded Portillo’s (PTLO) to Hold from Buy with a $13 price target The company reported disappointing same-restaurant-sales and traffic performance, with EBITDA above ...